EP
WST icon

Edgestream Partners’s West Pharmaceutical WST Stock Holding History

Edgestream Partners’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-37,754
Closed -$8.26M – 1088
2025
Q2 		$8.26M Buy
+37,754
New +$8.07M 0.23% 130
2023
Q3 		– Sell
-4,706
Closed -$1.8M – 1000
2023
Q2 		$1.8M Buy
4,706
+836
+22% +$299K 0.16% 208
2023
Q1 		$1.34M Buy
+3,870
New +$1.13M 0.15% 224
2022
Q1 		– Sell
-3,504
Closed -$1.64M – 652
2021
Q4 		$1.64M Sell
3,504
-5,386
-61% -$2.32M 0.1% 257
2021
Q3 		$3.77M Sell
8,890
-2,757
-24% -$1.16M 0.23% 150
2021
Q2 		$4.18M Sell
11,647
-5,246
-31% -$1.73M 0.25% 145
2021
Q1 		$4.76M Buy
16,893
+2,678
+19% +$766K 0.27% 146
2020
Q4 		$4.03M Buy
+14,215
New +$3.99M 0.2% 155

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return

Edgestream Partners's WST Position: Q3 2025 in Review

Edgestream Partners sold out of West Pharmaceutical (WST) in Q3 2025, closing a stake of 37,754 shares — an estimated $8.26M sold.

Edgestream Partners first reported a position in WST in Q4 2020 and held it in 8 quarters. The position peaked at $8.26M in Q2 2025. 758 funds tracked by Wall St. Rank hold WST as of Q3 2025.

  • Edgestream Partners reported no remaining West Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Edgestream Partners sold 37,754 West Pharmaceutical shares in Q3 2025, an estimated $8.26M.
  • Edgestream Partners first reported a position in West Pharmaceutical in Q4 2020 and held it in 8 quarters.
  • Edgestream Partners's West Pharmaceutical position peaked at $8.26M in Q2 2025.
  • 758 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2025.

Based on Edgestream Partners's 13F filing for Q3 2025, filed 12 Nov 2025.